Eintrag weiter verarbeiten
Antihypertensive Actions of the Novel Nonpeptide Endothelin Receptor Antagonist SB 209670
Gespeichert in:
| Zeitschriftentitel: | Hypertension |
|---|---|
| Personen und Körperschaften: | , , , , , |
| In: | Hypertension, 25, 1995, 4, S. 818-822 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Ovid Technologies (Wolters Kluwer Health)
|
| Schlagwörter: |
| author_facet |
Douglas, Stephen A. Gellai, Miklos Ezekiel, Mildred Feuerstein, Giora Z. Elliott, John D. Ohlstein, Eliot H. Douglas, Stephen A. Gellai, Miklos Ezekiel, Mildred Feuerstein, Giora Z. Elliott, John D. Ohlstein, Eliot H. |
|---|---|
| author |
Douglas, Stephen A. Gellai, Miklos Ezekiel, Mildred Feuerstein, Giora Z. Elliott, John D. Ohlstein, Eliot H. |
| spellingShingle |
Douglas, Stephen A. Gellai, Miklos Ezekiel, Mildred Feuerstein, Giora Z. Elliott, John D. Ohlstein, Eliot H. Hypertension Antihypertensive Actions of the Novel Nonpeptide Endothelin Receptor Antagonist SB 209670 Internal Medicine |
| author_sort |
douglas, stephen a. |
| spelling |
Douglas, Stephen A. Gellai, Miklos Ezekiel, Mildred Feuerstein, Giora Z. Elliott, John D. Ohlstein, Eliot H. 0194-911X 1524-4563 Ovid Technologies (Wolters Kluwer Health) Internal Medicine http://dx.doi.org/10.1161/01.hyp.25.4.818 <jats:p> <jats:italic>Abstract</jats:italic> Indirect evidence has implicated endothelin-1 in the pathogenesis of hypertension. In the present study we examined such a role directly with SB 209670, a novel nonpeptide endothelin receptor antagonist. The antihypertensive and hemodynamic effects of SB 209670 were examined in conscious, unrestrained spontaneously hypertensive (SHR), normotensive Wistar-Kyoto (WKY), and renin-hypertensive rats. Sustained intravenous infusion of SB 209670 (10 μg · kg <jats:sup>−1</jats:sup> · min <jats:sup>−1</jats:sup> for 6 hours) produced a significant, reversible reduction in mean arterial pressure in SHR but not in WKY rats. The antihypertensive response to 10 μg · kg <jats:sup>−1</jats:sup> · min <jats:sup>−1</jats:sup> SB 209670 (∼25 mm Hg reduction in blood pressure) was associated with bradycardia (16% decrease in heart rate) but only a minimal reduction (3%) in cardiac output, because stroke volume was elevated (by 15%). Therefore, the antihypertensive effect of SB 209670 resulted from a decrease (13%) in total peripheral resistance. A sustained antihypertensive effect could also be observed after intraduodenal administration of SB 209670 (3 mg/kg) in conscious SHR (reduction of ∼35 mm Hg 5 hours after administration). SB 209670 (3 mg/kg intravenous bolus) did not alter the pressor response or tachycardia observed in pithed SHR after stimulation of thoracolumbar sympathetic outflow. SB 209670 was also antihypertensive in renin-hypertensive rats, lowering blood pressure to an extent similar to that observed in SHR. Thus, the data presented provide evidence to support a role for endothelin-1 in the pathophysiology of two animal models of hypertension. </jats:p> Antihypertensive Actions of the Novel Nonpeptide Endothelin Receptor Antagonist SB 209670 Hypertension |
| doi_str_mv |
10.1161/01.hyp.25.4.818 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE2MS8wMS5oeXAuMjUuNC44MTg |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE2MS8wMS5oeXAuMjUuNC44MTg |
| institution |
DE-D275 DE-Bn3 DE-Brt1 DE-D161 DE-Zwi2 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 |
| imprint |
Ovid Technologies (Wolters Kluwer Health), 1995 |
| imprint_str_mv |
Ovid Technologies (Wolters Kluwer Health), 1995 |
| issn |
0194-911X 1524-4563 |
| issn_str_mv |
0194-911X 1524-4563 |
| language |
English |
| mega_collection |
Ovid Technologies (Wolters Kluwer Health) (CrossRef) |
| match_str |
douglas1995antihypertensiveactionsofthenovelnonpeptideendothelinreceptorantagonistsb209670 |
| publishDateSort |
1995 |
| publisher |
Ovid Technologies (Wolters Kluwer Health) |
| recordtype |
ai |
| record_format |
ai |
| series |
Hypertension |
| source_id |
49 |
| title |
Antihypertensive Actions of the Novel Nonpeptide Endothelin Receptor Antagonist SB 209670 |
| title_unstemmed |
Antihypertensive Actions of the Novel Nonpeptide Endothelin Receptor Antagonist SB 209670 |
| title_full |
Antihypertensive Actions of the Novel Nonpeptide Endothelin Receptor Antagonist SB 209670 |
| title_fullStr |
Antihypertensive Actions of the Novel Nonpeptide Endothelin Receptor Antagonist SB 209670 |
| title_full_unstemmed |
Antihypertensive Actions of the Novel Nonpeptide Endothelin Receptor Antagonist SB 209670 |
| title_short |
Antihypertensive Actions of the Novel Nonpeptide Endothelin Receptor Antagonist SB 209670 |
| title_sort |
antihypertensive actions of the novel nonpeptide endothelin receptor antagonist sb 209670 |
| topic |
Internal Medicine |
| url |
http://dx.doi.org/10.1161/01.hyp.25.4.818 |
| publishDate |
1995 |
| physical |
818-822 |
| description |
<jats:p>
<jats:italic>Abstract</jats:italic>
Indirect evidence has implicated endothelin-1 in the pathogenesis of hypertension. In the present study we examined such a role directly with SB 209670, a novel nonpeptide endothelin receptor antagonist. The antihypertensive and hemodynamic effects of SB 209670 were examined in conscious, unrestrained spontaneously hypertensive (SHR), normotensive Wistar-Kyoto (WKY), and renin-hypertensive rats. Sustained intravenous infusion of SB 209670 (10 μg · kg
<jats:sup>−1</jats:sup>
· min
<jats:sup>−1</jats:sup>
for 6 hours) produced a significant, reversible reduction in mean arterial pressure in SHR but not in WKY rats. The antihypertensive response to 10 μg · kg
<jats:sup>−1</jats:sup>
· min
<jats:sup>−1</jats:sup>
SB 209670 (∼25 mm Hg reduction in blood pressure) was associated with bradycardia (16% decrease in heart rate) but only a minimal reduction (3%) in cardiac output, because stroke volume was elevated (by 15%). Therefore, the antihypertensive effect of SB 209670 resulted from a decrease (13%) in total peripheral resistance. A sustained antihypertensive effect could also be observed after intraduodenal administration of SB 209670 (3 mg/kg) in conscious SHR (reduction of ∼35 mm Hg 5 hours after administration). SB 209670 (3 mg/kg intravenous bolus) did not alter the pressor response or tachycardia observed in pithed SHR after stimulation of thoracolumbar sympathetic outflow. SB 209670 was also antihypertensive in renin-hypertensive rats, lowering blood pressure to an extent similar to that observed in SHR. Thus, the data presented provide evidence to support a role for endothelin-1 in the pathophysiology of two animal models of hypertension.
</jats:p> |
| container_issue |
4 |
| container_start_page |
818 |
| container_title |
Hypertension |
| container_volume |
25 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792340618673913868 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T16:06:51.391Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Antihypertensive+Actions+of+the+Novel+Nonpeptide+Endothelin+Receptor+Antagonist+SB+209670&rft.date=1995-04-01&genre=article&issn=1524-4563&volume=25&issue=4&spage=818&epage=822&pages=818-822&jtitle=Hypertension&atitle=Antihypertensive+Actions+of+the+Novel+Nonpeptide+Endothelin+Receptor+Antagonist+SB+209670&aulast=Ohlstein&aufirst=Eliot+H.&rft_id=info%3Adoi%2F10.1161%2F01.hyp.25.4.818&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792340618673913868 |
| author | Douglas, Stephen A., Gellai, Miklos, Ezekiel, Mildred, Feuerstein, Giora Z., Elliott, John D., Ohlstein, Eliot H. |
| author_facet | Douglas, Stephen A., Gellai, Miklos, Ezekiel, Mildred, Feuerstein, Giora Z., Elliott, John D., Ohlstein, Eliot H., Douglas, Stephen A., Gellai, Miklos, Ezekiel, Mildred, Feuerstein, Giora Z., Elliott, John D., Ohlstein, Eliot H. |
| author_sort | douglas, stephen a. |
| container_issue | 4 |
| container_start_page | 818 |
| container_title | Hypertension |
| container_volume | 25 |
| description | <jats:p> <jats:italic>Abstract</jats:italic> Indirect evidence has implicated endothelin-1 in the pathogenesis of hypertension. In the present study we examined such a role directly with SB 209670, a novel nonpeptide endothelin receptor antagonist. The antihypertensive and hemodynamic effects of SB 209670 were examined in conscious, unrestrained spontaneously hypertensive (SHR), normotensive Wistar-Kyoto (WKY), and renin-hypertensive rats. Sustained intravenous infusion of SB 209670 (10 μg · kg <jats:sup>−1</jats:sup> · min <jats:sup>−1</jats:sup> for 6 hours) produced a significant, reversible reduction in mean arterial pressure in SHR but not in WKY rats. The antihypertensive response to 10 μg · kg <jats:sup>−1</jats:sup> · min <jats:sup>−1</jats:sup> SB 209670 (∼25 mm Hg reduction in blood pressure) was associated with bradycardia (16% decrease in heart rate) but only a minimal reduction (3%) in cardiac output, because stroke volume was elevated (by 15%). Therefore, the antihypertensive effect of SB 209670 resulted from a decrease (13%) in total peripheral resistance. A sustained antihypertensive effect could also be observed after intraduodenal administration of SB 209670 (3 mg/kg) in conscious SHR (reduction of ∼35 mm Hg 5 hours after administration). SB 209670 (3 mg/kg intravenous bolus) did not alter the pressor response or tachycardia observed in pithed SHR after stimulation of thoracolumbar sympathetic outflow. SB 209670 was also antihypertensive in renin-hypertensive rats, lowering blood pressure to an extent similar to that observed in SHR. Thus, the data presented provide evidence to support a role for endothelin-1 in the pathophysiology of two animal models of hypertension. </jats:p> |
| doi_str_mv | 10.1161/01.hyp.25.4.818 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE2MS8wMS5oeXAuMjUuNC44MTg |
| imprint | Ovid Technologies (Wolters Kluwer Health), 1995 |
| imprint_str_mv | Ovid Technologies (Wolters Kluwer Health), 1995 |
| institution | DE-D275, DE-Bn3, DE-Brt1, DE-D161, DE-Zwi2, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229 |
| issn | 0194-911X, 1524-4563 |
| issn_str_mv | 0194-911X, 1524-4563 |
| language | English |
| last_indexed | 2024-03-01T16:06:51.391Z |
| match_str | douglas1995antihypertensiveactionsofthenovelnonpeptideendothelinreceptorantagonistsb209670 |
| mega_collection | Ovid Technologies (Wolters Kluwer Health) (CrossRef) |
| physical | 818-822 |
| publishDate | 1995 |
| publishDateSort | 1995 |
| publisher | Ovid Technologies (Wolters Kluwer Health) |
| record_format | ai |
| recordtype | ai |
| series | Hypertension |
| source_id | 49 |
| spelling | Douglas, Stephen A. Gellai, Miklos Ezekiel, Mildred Feuerstein, Giora Z. Elliott, John D. Ohlstein, Eliot H. 0194-911X 1524-4563 Ovid Technologies (Wolters Kluwer Health) Internal Medicine http://dx.doi.org/10.1161/01.hyp.25.4.818 <jats:p> <jats:italic>Abstract</jats:italic> Indirect evidence has implicated endothelin-1 in the pathogenesis of hypertension. In the present study we examined such a role directly with SB 209670, a novel nonpeptide endothelin receptor antagonist. The antihypertensive and hemodynamic effects of SB 209670 were examined in conscious, unrestrained spontaneously hypertensive (SHR), normotensive Wistar-Kyoto (WKY), and renin-hypertensive rats. Sustained intravenous infusion of SB 209670 (10 μg · kg <jats:sup>−1</jats:sup> · min <jats:sup>−1</jats:sup> for 6 hours) produced a significant, reversible reduction in mean arterial pressure in SHR but not in WKY rats. The antihypertensive response to 10 μg · kg <jats:sup>−1</jats:sup> · min <jats:sup>−1</jats:sup> SB 209670 (∼25 mm Hg reduction in blood pressure) was associated with bradycardia (16% decrease in heart rate) but only a minimal reduction (3%) in cardiac output, because stroke volume was elevated (by 15%). Therefore, the antihypertensive effect of SB 209670 resulted from a decrease (13%) in total peripheral resistance. A sustained antihypertensive effect could also be observed after intraduodenal administration of SB 209670 (3 mg/kg) in conscious SHR (reduction of ∼35 mm Hg 5 hours after administration). SB 209670 (3 mg/kg intravenous bolus) did not alter the pressor response or tachycardia observed in pithed SHR after stimulation of thoracolumbar sympathetic outflow. SB 209670 was also antihypertensive in renin-hypertensive rats, lowering blood pressure to an extent similar to that observed in SHR. Thus, the data presented provide evidence to support a role for endothelin-1 in the pathophysiology of two animal models of hypertension. </jats:p> Antihypertensive Actions of the Novel Nonpeptide Endothelin Receptor Antagonist SB 209670 Hypertension |
| spellingShingle | Douglas, Stephen A., Gellai, Miklos, Ezekiel, Mildred, Feuerstein, Giora Z., Elliott, John D., Ohlstein, Eliot H., Hypertension, Antihypertensive Actions of the Novel Nonpeptide Endothelin Receptor Antagonist SB 209670, Internal Medicine |
| title | Antihypertensive Actions of the Novel Nonpeptide Endothelin Receptor Antagonist SB 209670 |
| title_full | Antihypertensive Actions of the Novel Nonpeptide Endothelin Receptor Antagonist SB 209670 |
| title_fullStr | Antihypertensive Actions of the Novel Nonpeptide Endothelin Receptor Antagonist SB 209670 |
| title_full_unstemmed | Antihypertensive Actions of the Novel Nonpeptide Endothelin Receptor Antagonist SB 209670 |
| title_short | Antihypertensive Actions of the Novel Nonpeptide Endothelin Receptor Antagonist SB 209670 |
| title_sort | antihypertensive actions of the novel nonpeptide endothelin receptor antagonist sb 209670 |
| title_unstemmed | Antihypertensive Actions of the Novel Nonpeptide Endothelin Receptor Antagonist SB 209670 |
| topic | Internal Medicine |
| url | http://dx.doi.org/10.1161/01.hyp.25.4.818 |